Actively Recruiting
Phase II Study of Mosunetuzumab Combined with CHOP as First Treatment for Patients Aged 18 to 79 with Richters Syndrome
Led by GELLC (Grupo Español de Leucemia Linfocítica Crónica) · Updated on 2025-04-13
34
Participants Needed
16
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate if the drug Mosunetuzumab works to treat Richters Syndrome and to understand its safety. It focuses on patients with Richters Syndrome who have never received therapy before. This Phase II clinical trial is sponsored by the Spanish Group of Chronic Lymphocytic Leukemia GELLC and seeks to assess the effectiveness of Mosunetuzumab combined with CHOP chemotherapy. Participants will receive six cycles of Mosunetuzumab combined with CHOP chemotherapy. After these induction cycles, patients who have stable disease or a partial or complete response but are not candidates for cellular therapy will continue treatment with Mosunetuzumab alone for eleven additional 21-day cycles, lasting about ten months. This treatment continues until disease progression or unacceptable side effects occur. During the study, participants will visit the clinic every 2 to 3 weeks for checkups and tests. Researchers will monitor how well the treatment works after the induction and maintenance phases, track any side effects, and evaluate how long patients stay on treatment. The total treatment period can last up to approximately 16 months, and safety and effectiveness will be carefully assessed throughout.
CONDITIONS
Brief Title
CHOP Plus Mosunetuzumab as First Line in Patients With Richter´s Syndrome: a Phase II Study of the Spanish Group of CLL
Research Team
A
Ana Méndez, Sponsor representative
T
Teresa Pascual Tome, CRO representative
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here